Study wrapper · #1265
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
Editor's note
A genuinely useful comparative design — same models, same readouts, three agents — and the pathway dissection (PI3K-AKT for semaglutide, PI3K-AKT plus PPAR for tirzepatide, PI3K-AKT plus NF-kB for retatrutide) gives mechanism rather than just an endpoint. The limits are the usual ones: mouse ureteral-obstruction and ageing models are aggressive surrogates for human chronic kidney disease, and a single dose level per agent cannot establish that retatrutide is more potent in people. The authors frame it as hypothesis-generating, which is the right register. Retatrutide remains investigational and unapproved.
Plain-language abstract
Researchers compared semaglutide, tirzepatide and retatrutide head to head for effects on kidney scarring in mice with surgically obstructed ureters and in aged mice, plus human kidney cells. All three reduced fibrosis markers, but through partly different signalling pathways, and retatrutide had the largest effect at the doses tested. None of the animals were diabetic, which is the point: the effect did not appear to depend on glucose lowering.